S2 Fig. Cross-validation of predicted white blood cell (WBC) counts from personalised models (PMs) M1-M12 and measured WBC counts for six patients treated with D135. All but one cycle were used for personalisation and the last cycle for cross-validation. For patients (a)-(e) the PMs can predict the WBC count decrease after Ara-C administration in the last cycle where models M10 and M12 have a slower WBC recovery than M5. For patient (f) the WBC recovery from the PMs starts to early compared to the measured WBC counts.